Myostatin: genetic variants, therapy and gene doping
Since its discovery, myostatin (MSTN) has been at the forefront of muscle therapy research because intrinsic mutations or inhibition of this protein, by either pharmacological or genetic means, result in muscle hypertrophy and hyperplasia. In addition to muscle growth, MSTN inhibition potentially di...
Saved in:
Main Authors: | André Katayama Yamada (Author), Rozangela Verlengia (Author), Carlos Roberto Bueno Junior (Author) |
---|---|
Format: | Book |
Published: |
Universidade de São Paulo,
2012-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel splice variant of the human MSTN gene encodes a myostatin‐specific myostatin inhibitor
by: Kazuhiro Maeta, et al.
Published: (2023) -
Serum myokines as potential biomarkers of myostatin inhibition in sport doping: a preliminary study on their baseline levels in elite athletes
by: Francesco Donati, et al.
Published: (2023) -
Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male
by: Der-Sheng Han, et al.
Published: (2017) -
Genetic Doping and Health Damages
by: AA Fallahi Fallahi, et al.
Published: (2011) -
Genetic Doping and Health Damages
by: AA Fallahi Fallahi, et al.
Published: (2011)